Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: All patients suffered from smoking-related COPD without alpha 1 antitrypsin deficiency, and those with a smoking history of 10 pack-year or more including current smoker were selected for this study. In addition, as a substitute for LAMA and LABA during the washout period, patients who responded to symptoms with short-acting treatment were selected as eligible for inclusion. After receiving a thorough explanation of the study, patients who provided written consent were enrolled in the study
Exclusion criteria
Exclusion criteria: Patients with dysuria due to prostate hypertrophy, glaucoma, severe heart failure, exacerbation and/or respiratory infection within 3 months, prior history of lung surgery, severe heart disease, or impairment or difficulty in walking due to motor or cognitive dysfunction were excluded. Exacerbation history criteria was defined as an acute worsening of respiratory symptoms that result in additional therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was defined as decrease in inspiratory capacity (IC) from rest by metronome-paced incremental hyperventilation(MPIH), which is an index of dynamic lung hyperinflation(DLH). after 8 weeks with treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes were COPD assessment test (CAT), FEV1, and 6-minute walking distance (6MWD). In addition to, as in previous studies, we investigated whether there are correlations between changes by treatment in DLH and exercise tolerance or dyspnea on exercise after 8weeks with treatment. | — |
Countries
Japan
Contacts
Shinshu University Hospital Department of Rehabilitation